Targeted TH signaling therapy has demonstrated significant success in various medical fields, including pulmonary fibrosis, where the TH analog GC-1 (Sobetirome) exerts antifibrotic effects by activating TRβ, enhancing mitochondrial function, and inhibiting fibroblast activation and ECM deposition [224, 330–332]. The gene discussed is TH; the disease is pulmonary fibrosis.